Works by Han, Sae-Won

Results: 98
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.

    Published in:
    British Journal of Cancer, 2023, v. 129, n. 2, p. 374, doi. 10.1038/s41416-023-02300-3
    By:
    • Ryoo, Seung-Bum;
    • Heo, Sunghoon;
    • Lim, Yoojoo;
    • Lee, Wookjae;
    • Cho, Su Han;
    • Ahn, Jongseong;
    • Kang, Jun-Kyu;
    • Kim, Su Yeon;
    • Kim, Hwang-Phill;
    • Bang, Duhee;
    • Kang, Sung-Bum;
    • Yu, Chang Sik;
    • Oh, Seong Taek;
    • Park, Ji Won;
    • Jeong, Seung-Yong;
    • Kim, Young-Joon;
    • Park, Kyu Joo;
    • Han, Sae-Won;
    • Kim, Tae-You
    Publication type:
    Article
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    Pragmatic nationwide master observational trial based on genomic alterations in advanced solid tumors: KOrean Precision Medicine Networking Group Study of MOlecular profiling guided therapy based on genomic alterations in advanced Solid tumors (KOSMOS)-II study protocol KCSG AL-22–09

    Published in:
    BMC Cancer, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12885-024-12338-y
    By:
    • Kim, Sun Young;
    • Kim, Jee Hyun;
    • Kim, Tae-Yong;
    • Park, Sook Ryun;
    • Yoon, Shinkyo;
    • Lee, Soohyeon;
    • Lee, Se-Hoon;
    • Kim, Tae Min;
    • Han, Sae-Won;
    • Kim, Hye Ryun;
    • Yun, Hongseok;
    • Lee, Sejoon;
    • Kim, Jihun;
    • Choi, Yoon-La;
    • Choi, Kui Son;
    • Chae, Heejung;
    • Ryu, Hyewon;
    • Lee, Gyeong-Won;
    • Zang, Dae Young;
    • Ahn, Joong Bae
    Publication type:
    Article
    35

    Total neoadjuvant therapy with short-course radiotherapy Versus long-course neoadjuvant chemoradiotherapy in Locally Advanced Rectal cancer, Korean trial (TV-LARK trial): study protocol of a multicentre randomized controlled trial.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-11177-7
    By:
    • Kim, Min Jung;
    • Lee, Dae Won;
    • Kang, Hyun-Cheol;
    • Park, Ji Won;
    • Ryoo, Seung-Bum;
    • Han, Sae-Won;
    • Kim, Kyung Su;
    • Chie, Eui Kyu;
    • Oh, Jae Hwan;
    • Jeong, Woon Kyung;
    • Kim, Byoung Hyuck;
    • Nam, Eun Mi;
    • Jeong, Seung-Yong
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48
    49
    50

    HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 1, p. 109, doi. 10.1007/s00280-013-2174-1
    By:
    • Kim, Ji-Won;
    • Kim, Jee;
    • Im, Seock-Ah;
    • Kim, Yu;
    • Han, Hye-Suk;
    • Kim, Jin-Soo;
    • Lee, Kyung-Hun;
    • Kim, Tae-Yong;
    • Han, Sae-Won;
    • Jeon, Yoon;
    • Oh, Do-Youn;
    • Kim, Tae-You;
    • Park, In
    Publication type:
    Article